Sovremennye aspektyfarmakoterapii arterial'noygipertenzii. Vozmozhnosti urapidila


Cite item

Full Text

Abstract

About the authors

T E Morozova

References

  1. Шальнова С.А., Баланова Ю.А., Константинов В. В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. РКЖ. 2006; 4: 45-50.
  2. Ezzati M, Lopez A, Rodgers A, Vander Hoorn S et al. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Ge-neva: World Health Organization 2004.
  3. Chobanian AV. Shattuck Lecture. The hypertension paradox - more uncontrolled disease de-spite improved therapy. N Engl J Med 2009; 361: 878-87.
  4. Диагностика и лечение артериальной гипертонии. Рекомендаци РМОАГ/ВНОК, четвертый пересмотр. 2010.
  5. Hunt KJ, Resendez RG, Williams K et al. San Antonio Heart StudyNational Cho-lesterol Edu-cation Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110 (10): 1251-7.
  6. Stamler J, Vaccaro O, Neaton JD et al. for the Multiple Risk Factor Intervention Trial Re-search Group. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
  7. Parving H.H. Hypertension and diabetes: the scope of the problem. Blood pressure 2001; 10 (Suppl. 2): 25-31.
  8. Мancia G, Grassi G, Zanchetti A. Newonset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3-10.
  9. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network metaanalysis. Lancet 2007; 369: 201-7.
  10. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arte-rial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536.
  11. Zusman RM. The role of alpha 1-blockers in combination therapy for hypertension. Int J Clin Pract 2000; 54: 36-40.
  12. Verdecchia P, Staessen JA, Angeli F et al. Usual versus tight control of systolic blood pres-sure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009; 374 (9689): 525-33.
  13. van Zwieten PA, Blauw GJ, van Brummelen P. Pharmacological profile of anti-hypertensive drugs with serotonin receptor and alpha-adrenoceptor activity. Drugs 1990; 40 (Suppl. 4): 1-8.
  14. Heran BS, Galm BP, Wright JM. Blood pressure lowering efficacy of alpha blockers for pri-mary hypertension. Cochrane Database Syst Rev 2009; 4: CD004643.
  15. Fozard JR, Mir AK. Are 5HT-receptors involved in the antihypertensive effects of urapidil. Brit J Pharmacol 1987; 90: 24P.
  16. Gross G, Hanft G, Kolassa N. Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5HT) binding sites of the 5HT1A-sub-type and for a1-adrenoceptor binding sites. Naunyn-Schmiedeberg. Arch Pharmacol 1987; 336: 597-601.
  17. Giilis RA, Kellar KJ, Quest JA et al. Experimental studies on the neurocardiovas-cular ef-fects of urapidil. Drugs 1988; 35 (Suppl. 6): 20-33.
  18. Kolassa N, Beller KD, Sanders KH. Involvement of brain 5HT1A-receptors in the hypoten-sive response to urapidil. Am J Cardiol 1989; 64: 7-10D.
  19. Sanders KH, Beller KD, Eltze M et al. Urapidil and some anaglogs with high affinities for serotonin-1A and b1-adrenoceptor binding sites show potent hypotensive activity upon central administration. Current Оpinion Cardiol 1989; 4 (Suppl. 4): S49-55.
  20. Fariello R, Boni E, Corda L, Zaninelli A et al. Influence of a new multifactorial antihyperten-sive on blood pressure and metabolic profile in essential hypertension associated with non-insulin-dependent diabetes mellitus. Eur Heart J 1992; 13 (Suppl. A): 65-9.
  21. Oren S, Turkot S, Paran E, Flandra O et al. Efficacy and tolerability of slow release urapidil (ebrantil) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM). J Hum Hypertens 1996; 10: 123-7.
  22. Goto Y. Effects of sustained-release urapidil on essential hypertension and hyperlipidaemia: a multicenter clinical trial. Curr Ther Res 1992; 51: 870-6.
  23. Ferrara LA, Leonetti G, Fogari R, Mazzola C et al. Urapidil in hypercholesterolemic hyper-tensive patients. Blood Press Suppl 1994; 4: 39-44.
  24. Pattenier JW, von Heusinger FC. Effect of urapidil treatment on lipid metabolism in patients with hypertension. Royal Soc Med Int Congr Symp 1992; 196: 61-7.
  25. Alijotas-Reig J, Bove-Farre I, De Cabo-Frances F et al. Effectiveness and safety of prehospi-tal urapidil for hypertensive emergencies. Am J Emerg Med 2001; 19: 130-3.
  26. Cherney D, Strans Sh. Management of patients with hypertensive urgencies and emergen-cies. J Gen Intern Med 2002; 17: 937-94.
  27. Елагин Р.И. Адренергические средства: альфа-адреноблокаторы. Cons. Med. 2003; 7: 1-6.
  28. Rosei EA, Salvetti M, Farsang C. Лечение осложненных и неосложненных гипертонических кризов. Актуальные вопросы болезней сердца и сосудов. 2007; 2: 66-8.
  29. Liebau H, Wurst W, Harder I, Solleder P. Metabolically neutral therapy of hyper-tension. An open, multicenter, prospective long-term study of the tolerance, safety and effective-ness of ura-pidil. Fortschr Med 1988; 106: 651-4.
  30. Liebau H, Solleder P, Harder I, Wurst W. Long-term antihypertensive therapy with urapidil. A 3-year open, multicenter trial of tolerance, safety and effectiveness. Fortschr Med 1990; 108: 325-28.
  31. Haerlin R. Treatment of primary and secondary hypertension. Long-term use of urapidil (Ebrantil®). Clinical Trials J 1985; 22: 215-25.
  32. Dooley M, Goa KL. Urapidil. A reappraisal of its use in the management of hypertension. Drugs 1998; 56: 929-55.
  33. Zanchetti A. Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Blood Press Suppl 1995; 3: 38-46.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies